Group items tagged

The FY18 PH/TBIRP CTRR-CTDA mechanism is being offered for the first time in FY18 and is intended to support the development of clinical trials focused on TBI rehabilitation interventions in the FY18 PH/TBIRP CTRR-CTDA focus areas described in II.A.1. Development of clinical trials focusing on rehabilitation strategies in patients with mild TBI is highly encouraged. The proposed research must be relevant to active duty Service members, Veterans, and their beneficiaries. It is expected that any research findings will also provide benefit to the general population. The PH/TBIRP CTRR-CTDA mechanism supports the design and development of the research resources necessary to serve as a foundation for investigator-initiated clinical trials under future PH/TBIRP CTRR-Clinical Trial Award with the potential to develop knowledge and material products for rehabilitation and restoration of function following TBI. Principal Investigators (PIs) should explain how the proposed future clinical trial will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines.

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

This Funding Opportunity Announcement (FOA) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this FOA is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders. While minimal or no preliminary data are expected to be described, applications should clearly indicate the significance of the proposed work, that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate.

The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.

The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.   

The Division of Graduate Education announces the Graduate Research Internship Program (GRIP) to provide professional development to NSF Graduate Research Fellows through internships developed in partnership with federal agencies (see the GRIP website for a current list of partner agencies). Through this initiative, NSF Graduate Fellows will participate in mission-related, collaborative research under the guidance of host research mentors at federal facilities and national laboratories. The internship experiences will support Fellows with developing expertise in critical STEM areas, enhancing professional skills, developing networks, and preparing for a wide array of career options. The sponsor agencies will benefit by engaging Fellows in mission-critical projects, helping to develop a highly skilled U.S. workforce in areas of national need.

The Science of Science & Innovation Policy (SciSIP) program supports research designed to advance the scientific basis of science and innovation policy. Research funded by the program thus develops, improves and expands models, analytical tools, data and metrics that can be applied in the science policy decision making process. For example, research proposals may develop behavioral and analytical conceptualizations, frameworks or models that have applications across a broad array of SciSIP challenges, including the relationship between broader participation and innovation or creativity. Proposals may also develop methodologies to analyze science and technology data, and to convey the information to a variety of audiences. Researchers are also encouraged to create or improve science and engineering data, metrics and indicators reflecting current discovery, particularly proposals that demonstrate the viability of collecting and analyzing data on knowledge generation and innovation in organizations. Among the many research topics supported are:examinations of the ways in which the contexts, structures and processes of science and engineering research are affected by policy decision, the evaluation of the tangible and intangible returns from investments in science and from investments in research and development, the study of structures and processes that facilitate the development of usable knowledge, theories of creative processes and their transformation into social and economic outcomes, the collection, analysis and visualization of new data describing the scientific and engineering enterprise. The SciSIP program invites the participation of researchers from all of the social, behavioral and economic sciences as well as those working in domain-specific applications such as chemistry, biology, physics, or nanotechnology. The program welcomes proposals for individual or multi-investigator research projects, doctoral dissertation improvement awards, conferences, wo

The U.S. Army Medical Research and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. The scope of this effort and the priorities attached to specific projects are influenced by changes in military and civilian medical science and technology, operational requirements, military threat assessments, and national defense strategies. The extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC. General information on USAMRMC can be obtained at https://mrmc.detrick.army.mil/. This Fiscal Year 2015 (FY15) Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas and is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016. In accordance with FAR 6.102, projects funded under this BAA must be for basic and applied research and that part of development not related to the development of a specific system or hardware procurement. Projects must be for scientific study and experimentation directed toward advancing the state-of-the-art or increasing knowledge or understanding rather than focusing on a specific system or hardware solution. Research and development funded through this BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge. This FY15 BAA is continuously open for a 12-month period, from October 1, 2014 through September 30, 2015, at 11:59 p.m. Eastern Time. Submission of a pre-proposal/pre-application is required and must be submitted through the new electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/). Pre-proposal/pre-applications may be submitted at any time throughout the 12-month period. If the USAMRMC is interested in rece

The OPORP Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding of and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies. Studies are sought that: * Compare different patient care approaches. * Include patient-centric outcome assessments. * Have the potential to generate new knowledge that can be developed into new clinical practice guidelines, and/or new prescription algorithms for prosthetic and orthotic devices. * Have the potential to develop new technology for improved prosthetic and orthotic devices, therefore improving patient outcomes. * Provide information on quality of life, reintegration, and/or return to duty/return to work as it pertains to those patients who use a prosthetic or orthotic device due to limb trauma. All applications must demonstrate direct relevance to Service Members and Veterans with traumatic extremity injury and/or amputation using prosthetics and orthotic devices. Examples of studies that are appropriate for submission to the FY14 OPORA include, but are not limited to, examination of the

The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD. Applications must focus on developing robust and precise imaging markers. Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets. Imaging modalities can include PET, SPECT and MRI. Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets. Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.

The International Research Experiences for Students (IRES) program supports international research and research-related activities for U.S. science and engineering students. The IRES program contributes to development of a diverse, globally-engaged workforce with world-class skills. IRES focuses on active research participation by undergraduate or graduate students in high quality international research, education and professional development experiences in NSF-funded research areas. The overarching, long-term goal of the IRES program is to enhance U.S. leadership in research and education and to strengthen economic competitiveness through training the next generation of research leaders. This solicitation features three mechanisms; proposers are required to select one of the following tracks to submit their proposal. Track I focuses on the development of world-class research skills in international cohort experiences. Track II is dedicated to targeted, intensive learning and training opportunities that leverage international knowledge at the frontiers of research. Track III supports U.S. institutional collaborations to develop, implement and evaluate innovative models for high-impact, large-scale international research and professional development experiences for U.S. graduate students. Student participants supported by IRES funds must be citizens, nationals, or permanent residents of the United States. Students do not apply directly to NSF to participate in IRES activities. Students apply to NSF-funded investigators who receive IRES awards. To identify appropriate IRES projects, students should consult the directory of active IRES awards. All PIs, co-PIs and Senior Personnel on IRES proposals must be from U.S. based institutions.

The Bill & Melinda Gates Foundation has issued an Request for Proposals for research that will lead to the development of a universal influenza vaccine Part of the foundation's Grand Challenges program, the goal of the foundation's Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development initiative is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic. While other funders are supporting development of universal Influenza vaccines, three things set this Grand Challenge apart. The Gates Foundation seeks to fund ideas that are bold and innovative, bridging the funding 'valley of death' to translate these novel approaches into products ready for human clinical trials. It also aims to encourage interdisciplinary collaboration and cross-fertilization of ideas from outside the traditional influenza research community. Third, it seeks completely transformative approaches rather than incremental research.

The vision for the Human BioMolecular Atlas Program (HuBMAP) is to catalyze development of a framework for mapping of the human body at high resolution to transform our understanding of tissue organization and function. This will be achieved by: Accelerating the development of the next generation of tools and techniques for constructing high resolution spatial tissue maps that quantify multiple types of biomolecules either sequentially or simultaneously; Generating foundational 3D tissue maps using validated high-content, high-throughput imaging and omics assays; Establishing an open data platform that will develop novel approaches to integrating, visualizing and modelling imaging and omics data to build multi-dimensional maps, and making data rapidly findable, accessible, interoperable, and reusable by the global research community; Coordinating and collaborating with other funding agencies, programs, and the biomedical research community to build the framework and tools for mapping the human body; Supporting pilot projects that demonstrate the value of the resources developed by the program to study individual variation and tissue changes across the lifespan and the health-disease continuum. This program is funded through the NIH Common Fund as a short-term, goal-driven strategic investment, with deliverables intended to catalyze research across multiple biomedical research disciplines. The NIH Common Fund supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress.

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental grant (R21) applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this PA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development. 

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs utilize the K01 award to increase research workforce diversity by providing enhanced research career development opportunities.

The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse group of highly trained biomedical and behavioral scientists to address the Nation's biomedical workforce needs. The strategy is to promote effective partnerships between research-intensive institutions (RII) and institutions that have a historical mission or a demonstrated commitment to educating students from diverse backgrounds underrepresented in the biomedical and behavioral research enterprise of the nation. The IRACDA program provides support for a traditional mentored postdoctoral research experience at an RII combined with an opportunity for these fellows to develop critical academic skills, including teaching, through workshops and through mentored teaching assignments at a partner institution. The primary goals of the IRACDA program are to (1) develop a group of highly trained biomedical and behavioral scientists who have the necessary knowledge and skills to pursue independent research and teaching careers in academia; and (2) strengthen and modernize science educational offerings at partner institutions, and promote links between RII and the partner institution(s). 

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental grant (R21) applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this PA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development.